These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. What's new on the antimicrobial horizon? Song JH Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S207-13. PubMed ID: 19134521 [TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Rybak MJ Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721 [TBL] [Abstract][Full Text] [Related]
27. Vancomycin resistance: are there better glycopeptides coming? Linden PK Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904 [TBL] [Abstract][Full Text] [Related]
28. Biosynthesis, biotechnological production, and application of teicoplanin: current state and perspectives. Jung HM; Jeya M; Kim SY; Moon HJ; Kumar Singh R; Zhang YW; Lee JK Appl Microbiol Biotechnol; 2009 Sep; 84(3):417-28. PubMed ID: 19609520 [TBL] [Abstract][Full Text] [Related]
29. Susceptibility of methicillin-resistant Staphylococcus aureus to vancomycin, teicoplanin, linezolid, pristinamycin and other antibiotics. Samra Z; Ofer O; Shmuely H Isr Med Assoc J; 2005 Mar; 7(3):148-50. PubMed ID: 15792257 [TBL] [Abstract][Full Text] [Related]
32. Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program. Jones RN; Sader HS; Fritsche TR; Hogan PA; Sheehan DJ J Clin Microbiol; 2006 Jul; 44(7):2622-5. PubMed ID: 16825398 [TBL] [Abstract][Full Text] [Related]
34. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria. Decousser JW; Bourgeois-Nicolaos N; Doucet-Populaire F Expert Rev Anti Infect Ther; 2007 Aug; 5(4):557-71. PubMed ID: 17678421 [TBL] [Abstract][Full Text] [Related]
35. Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. Gould IM Int J Antimicrob Agents; 2008 Apr; 31 Suppl 2():1-9. PubMed ID: 18485997 [TBL] [Abstract][Full Text] [Related]
36. [Glycopeptide-induced cutaneous adverse reaction]. Nosbaum A; Rozières A; Ben Said B; Nicolas JF; Bérard F Ann Dermatol Venereol; 2010 May; 137(5):341-2. PubMed ID: 20470913 [No Abstract] [Full Text] [Related]
37. [Glycopeptides and the newborn infant's kidney]. Fanos V; Benini D; Vinco S; Pizzini C; Khoory BJ Pediatr Med Chir; 1997; 19(4):259-62. PubMed ID: 9508651 [TBL] [Abstract][Full Text] [Related]
38. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004). Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511 [TBL] [Abstract][Full Text] [Related]
39. Comparison of the MicroScan system and the agar dilution assay for Quinupristin/Dalfopristin susceptibility of Enterococcus faecium. Kim YR; Kim SI; Hur JA; Kim YJ; Wie SH; Park YJ; Kang MW Ann Clin Lab Sci; 2007; 37(3):260-2. PubMed ID: 17709691 [TBL] [Abstract][Full Text] [Related]
40. [Bacterial resistance to vancomycin and other glycopeptide antibiotics: an emerging threat]. Kłoszewska M; Markiewicz Z Postepy Biochem; 1999; 45(2):122-36. PubMed ID: 10581636 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]